Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences

Core Insights - Sionna Therapeutics is focused on developing innovative treatments for cystic fibrosis (CF) by normalizing the function of the CFTR protein [2] - The company is advancing a pipeline of small molecules aimed at correcting defects caused by the F508del genetic mutation, which is significant for improving clinical outcomes for CF patients [2] Company Overview - Sionna Therapeutics is a clinical-stage biopharmaceutical company dedicated to revolutionizing CF treatment through novel medicines [2] - The company's approach involves stabilizing the nucleotide binding domain 1 (NBD1) of the CFTR protein, which is believed to be crucial for enhancing patient quality of life [2] - Sionna is also developing complementary CFTR modulators to work synergistically with its NBD1 stabilizers [2] Investor Engagement - Sionna will participate in investor events, including the TD Cowen 46 Annual Health Care Conference on March 2, 2026, and the Leerink Partners Global Healthcare Conference on March 10, 2026 [4] - Live webcasts of these presentations will be available on Sionna's Investor Relations website, with replays accessible afterward [1]